IRAK4 (Q9NWZ3) variants and mutations
IRAK4 (also known as Q9NWZ3) is a human protein-coding gene encoding an interleukin-1 receptor-associated kinase 4 protein. It relays proximal signals from most Toll-like receptors and IL-1-family receptors. Biallelic loss-of-function variants cause recurrent invasive pyogenic bacterial infections, particularly in childhood, because inflammatory responses to these receptors are severely impaired. This analysis covers 816 IRAK4 variants and mutations. Of these, 73% have computational variant effect predictions. Disease context includes Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency, immunodeficiency 67, and inborn error of immunity. Example IRAK4 variants include N2K, N2S, and K3Q.
Variant analysis overview
- Gene: IRAK4
- Protein: Q9NWZ3
- UniProt accession: Q9NWZ3
- Organism: Homo sapiens
- Variants analyzed: 816
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 601 unspecified-consequence records; 16 frameshift variants; 74 synonymous variants; 102 missense variants; 8 stop-gained variants; 4 in-frame deletions; 1 in-frame insertions; 1 splice acceptor variant; 3 splice-region variants; 1 protein altering variant; 5 substitution
- Prediction scores: 595 variants have prediction scores (73% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency, immunodeficiency 67, inborn error of immunity, autoimmune disorder of central nervous system, immunodeficiency 33, congenital dyserythropoietic anemia, pericarditis, neurodegenerative disease, hereditary disease, alcohol drinking, stroke disorder, acute myeloid leukemia.
Protein structure and variant hotspots
- Protein features: 2 domains; 4 binding sites; 5 post-translational modification sites.
- Structural context: 569 variants have structural context.
- PTM context: 5 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable IRAK4 variants
Examples include N2K, N2S, K3Q, P4L, P4P, I5M, I5V, I5*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- N2K (p.Asn2Lys), rs1940358839, ClinGen CA384464341, ClinVar RCV001336326, Ensembl rs1940358839, CADD 22.00, PolyPhen-2 0.17, Uncertain significance, Immunodeficiency 67
- N2S (p.Asn2Ser), 1000Genomes rs561048547, gnomAD rs561048547, CADD 4.57, PolyPhen-2 0.01
- K3Q (p.Lys3Gln), rs752890848, ClinGen CA6522259, ClinVar RCV001877493, ExAC rs752890848, CADD 22.60, PolyPhen-2 0.03, Uncertain significance, Immunodeficiency 67
- P4L (p.Pro4Leu), ExAC rs750912907, gnomAD rs750912907, CADD 23.80, PolyPhen-2 0.12
- P4P (p.Pro4Pro), rs1287416995, gnomAD 12-43768123-C-G, CADD 4.00
- I5M (p.Ile5Met), gnomAD rs1206861423, CADD 21.00, PolyPhen-2 0.07
- I5V (p.Ile5Val), rs56312115, ClinGen CA6522261, ClinVar RCV000942009, UniProt VAR 040588, CADD 1.22, PolyPhen-2 0.00, Conflicting interpretations, Immunodeficiency 67
- I5* (p.Ile5Ter), gnomAD 12-43768120-AC-A, CADD 24.90
- T6P (p.Thr6Pro), ExAC rs780540482, TOPMed rs780540482, gnomAD rs780540482, CADD 24.30, PolyPhen-2 0.92
- T6A (p.Thr6Ala), gnomAD 12-43768127-A-G, CADD 23.60, PolyPhen-2 0.50
- T6T (p.Thr6Thr), rs1047274763, gnomAD 12-43768129-A-G, CADD 6.93
- P7L (p.Pro7Leu), TOPMed rs1940361748, gnomAD rs1940361748, CADD 22.70
- P7P (p.Pro7Pro), rs201400143, gnomAD 12-43768132-A-G, CADD 8.95
- S8* (p.Ser8Ter), gnomAD 12-43768134-C-G, CADD 35.00
- S8S (p.Ser8Ser), rs1940362471, gnomAD 12-43768135-A-G, CADD 10.90
- T9K (p.Thr9Lys), TOPMed rs1940362790
- T9T (p.Thr9Thr), rs749572231, gnomAD 12-43768138-A-C, CADD 9.03
- Y10C (p.Tyr10Cys), gnomAD 12-43768140-A-G, CADD 26.80, PolyPhen-2 0.89
- Y10Y (p.Tyr10Tyr), gnomAD 12-43768141-T-C, CADD 8.06
- V11G (p.Val11Gly), rs1940363408, ClinGen CA384464395, ClinVar RCV001234554, Ensembl rs1940363408, AlphaMissense 0.90, MetaLR 0.36, Uncertain significance, Immunodeficiency 67
- R12C (p.Arg12Cys), rs377584435, ClinGen CA129367, cosmic curated COSV71210, ClinVar RCV000023583, CADD 27.30, PolyPhen-2 1.00, Conflicting interpretations, Immunodeficiency 67; not provided
- R12H (p.Arg12His), rs370524518, ClinGen CA6522264, ClinVar RCV000791511, ESP rs370524518, CADD 28.50, PolyPhen-2 1.00, Uncertain significance, Immunodeficiency 67
- R12L (p.Arg12Leu), ESP rs370524518, ExAC rs370524518, TOPMed rs370524518, gnomAD rs370524518, CADD 28.50, PolyPhen-2 0.99, Uncertain significance, in IMD67
- R12P (p.Arg12Pro), gnomAD 12-43768146-G-C, CADD 28.90, PolyPhen-2 1.00
- C13* (p.Cys13Ter), gnomAD rs1388998649, CADD 34.00
- C13F (p.Cys13Phe), rs1163230363, NCI-TCGA Cosmic COSV7121, cosmic curated COSV71211, gnomAD rs1163230363, CADD 20.60, PolyPhen-2 0.00, Uncertain significance
- C13R (p.Cys13Arg), TOPMed rs1473391364, gnomAD rs1473391364, CADD 16.10, PolyPhen-2 0.02
- C13Y (p.Cys13Tyr), rs1163230363, ClinGen CA384464404, ClinVar RCV001234555, gnomAD rs1163230363, CADD 16.70, PolyPhen-2 0.06, Uncertain significance, Immunodeficiency 67
- L14F (p.Leu14Phe), ExAC rs748441973, gnomAD rs748441973, CADD 24.40, PolyPhen-2 0.99
- L14R (p.Leu14Arg), gnomAD 12-43768152-T-G, CADD 27.00, PolyPhen-2 0.99
- N15K (p.Asn15Lys), TOPMed rs1399010629, gnomAD rs1399010629
- N15S (p.Asn15Ser), rs772274120, ClinGen CA6522266, ClinVar RCV002785873, ExAC rs772274120, CADD 8.16, PolyPhen-2 0.00, Uncertain significance, Immunodeficiency 67
- N15Y (p.Asn15Tyr), gnomAD 12-43768154-A-T, CADD 22.50, PolyPhen-2 0.23
- N15N (p.Asn15Asn), gnomAD 12-43768156-T-C, CADD 8.59
- G17E (p.Gly17Glu), cosmic curated COSV10752, ExAC rs778057572, TOPMed rs778057572, gnomAD rs778057572, CADD 26.00, PolyPhen-2 0.81, Uncertain significance, Immunodeficiency 67; Inborn genetic diseases
- G17R (p.Gly17Arg), TOPMed rs1332080757, CADD 24.30, PolyPhen-2 0.28
- L18L (p.Leu18Leu), rs1338069687, gnomAD 12-43768163-C-T, CADD 7.07
- I19T (p.Ile19Thr), TOPMed rs1940367529
- I19I (p.Ile19Ile), rs1940367866, gnomAD 12-43768168-T-C, CADD 9.25
- R20W (p.Arg20Trp), rs143625818, ClinGen CA6522269, ClinVar RCV001220131, UniProt VAR 072889, CADD 26.80, PolyPhen-2 0.89, Uncertain significance, Immunodeficiency 67
- K21E (p.Lys21Glu), rs2540411380, ClinGen CA384464450, ClinVar RCV004403226, Uncertain significance, Inborn genetic diseases
- K21N (p.Lys21Asn), rs1282400178, gnomAD 12-43768173-AG-A, CADD 24.70
- K21K (p.Lys21Lys), rs775601867, gnomAD 12-43768174-G-A, CADD 10.20
- L22del (p.Leu22del), gnomAD 12-43768173-AGCT-, CADD 18.70
- L22L (p.Leu22Leu), rs762610309, gnomAD 12-43768177-G-A, CADD 9.27
- S23T (p.Ser23Thr), NCI-TCGA Cosmic COSV7121, cosmic curated COSV71210, Variant assessed as somatic; moderate impact.
- S23A (p.Ser23Ala), gnomAD 12-43768178-T-G, CADD 17.20, PolyPhen-2 0.00
- D24H (p.Asp24His), cosmic curated COSV10535
- D24Y (p.Asp24Tyr), cosmic curated COSV10658
- I26T (p.Ile26Thr), rs138116867, ClinGen CA6522273, ClinVar RCV001347836, UniProt VAR 072890, CADD 23.80, PolyPhen-2 0.34, Uncertain significance, Immunodeficiency 67
- I26V (p.Ile26Val), rs768548402, ClinGen CA6522272, ClinVar RCV003051165, ExAC rs768548402, CADD 22.00, PolyPhen-2 0.07, Uncertain significance, Immunodeficiency 67
- D27V (p.Asp27Val), gnomAD 12-43768191-A-T, CADD 27.30, PolyPhen-2 1.00
- P28L (p.Pro28Leu), NCI-TCGA Cosmic COSV1014, cosmic curated COSV10147, Variant assessed as somatic; moderate impact.
- P28T (p.Pro28Thr), ExAC rs761596704, gnomAD rs761596704
- P28S (p.Pro28Ser), gnomAD 12-43768193-C-T, CADD 25.20, PolyPhen-2 0.97
- Q29* (p.Gln29Ter), NCI-TCGA Cosmic COSV1014, cosmic curated COSV10147, Variant assessed as somatic; high impact.
- Q29P (p.Gln29Pro), rs2540411559, ClinGen CA384464506, ClinVar RCV003326054, CADD 22.80, PolyPhen-2 0.11, Uncertain significance, Congenital dyserythropoietic anemia
- E30* (p.Glu30Ter), rs1443126481, ClinGen CA384464512, ClinVar RCV000640676, TOPMed rs1443126481, CADD 36.00, Pathogenic
- E30Q (p.Glu30Gln), TOPMed rs1443126481, gnomAD rs1443126481, CADD 24.20, PolyPhen-2 0.86, Pathogenic
- E30del (p.Glu30del), gnomAD 12-43768196-CAAG-, CADD 20.70
- E30K (p.Glu30Lys), rs1245012022, gnomAD 12-43768198-AG-A, CADD 31.00
- E30E (p.Glu30Glu), gnomAD 12-43768201-A-G, CADD 12.70
- G31E (p.Gly31Glu), gnomAD rs1187447576, CADD 22.70, PolyPhen-2 0.56
- G31R (p.Gly31Arg), rs2137901159, ClinGen CA384464519, ClinVar RCV001883771, Ensembl rs2137901159, CADD 22.00, PolyPhen-2 0.05, Uncertain significance, Immunodeficiency 67
- G31V (p.Gly31Val), gnomAD 12-43768203-G-T, CADD 23.60, PolyPhen-2 0.68
- G31G (p.Gly31Gly), rs1367304662, gnomAD 12-43768204-A-T, CADD 7.95
- W32* (p.Trp32Ter), 1000Genomes rs1199041696, gnomAD rs1199041696, CADD 36.00
- W32R (p.Trp32Arg), gnomAD 12-43768205-T-C, CADD 28.30, PolyPhen-2 1.00
- K33E (p.Lys33Glu), gnomAD rs1476676306
- K33K (p.Lys33Lys), rs115877973, gnomAD 12-43768210-G-A, CADD 10.20
- K34M (p.Lys34Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K34N (p.Lys34Asn), gnomAD 12-43768213-G-T, CADD 21.80, PolyPhen-2 0.28
- L35I (p.Leu35Ile), rs1423382149, ClinGen CA384464550, ClinVar RCV001111119, TOPMed rs1423382149, CADD 15.40, PolyPhen-2 0.04, Uncertain significance, Immunodeficiency 67
- A36T (p.Ala36Thr), NCI-TCGA Cosmic COSV7121, cosmic curated COSV71210, Variant assessed as somatic; moderate impact.
- A36L (p.Ala36Leu), gnomAD 12-43768211-AAGTT, CADD 27.50
- A36D (p.Ala36Asp), gnomAD 12-43768218-C-A, CADD 25.30, PolyPhen-2 0.95
- A36A (p.Ala36Ala), rs1463697671, gnomAD 12-43768219-T-C, CADD 9.40
- V37A (p.Val37Ala), Ensembl rs1035506145, CADD 19.70, PolyPhen-2 0.00
- A38D (p.Ala38Asp), TOPMed rs1402262535, gnomAD rs1402262535, Uncertain significance
- A38G (p.Ala38Gly), rs1402262535, ClinGen CA384464571, ClinVar RCV000792389, TOPMed rs1402262535, CADD 22.40, PolyPhen-2 0.06, Uncertain significance, Immunodeficiency 67
- A38P (p.Ala38Pro), 1000Genomes rs565544986, ExAC rs565544986, TOPMed rs565544986, gnomAD rs565544986, CADD 21.30, PolyPhen-2 0.35, Uncertain significance
- A38T (p.Ala38Thr), rs565544986, ClinGen CA6522277, ClinVar RCV002920803, 1000Genomes rs565544986, CADD 18.60, PolyPhen-2 0.08, Uncertain significance, Inborn genetic diseases
- I39V (p.Ile39Val), rs113588409, UniProt VAR 072891, TOPMed rs113588409, CADD 23.40, PolyPhen-2 0.91, Benign
- I39I (p.Ile39Ile), rs141039652, gnomAD 12-43768228-T-A, CADD 11.10
- K40R (p.Lys40Arg), gnomAD 12-43768230-A-G, CADD 19.00, PolyPhen-2 0.00
- K41N (p.Lys41Asn), cosmic curated COSV71211, CADD 19.30, PolyPhen-2 0.03
- K41K (p.Lys41Lys), rs551138584, gnomAD 12-43768234-A-G, CADD 10.20
- P42T (p.Pro42Thr), rs1940376224, gnomAD 12-43768228-T-TA, CADD 26.00
- P42S (p.Pro42Ser), gnomAD 12-43768235-C-T, CADD 24.30, PolyPhen-2 0.73
- P42L (p.Pro42Leu), gnomAD 12-43768236-C-T, CADD 23.70, PolyPhen-2 0.19
- P42P (p.Pro42Pro), rs1205715377, gnomAD 12-43768237-A-G, CADD 11.00
- S43T (p.Ser43Thr), TOPMed rs1439113408
- p.Ser43dup, rs1940377066, gnomAD 12-43768235-C-CCA, CADD 18.50
- G44C (p.Gly44Cys), rs1565665934, Ensembl rs1565665934, AlphaMissense 0.56, MetaLR 0.52, Variant assessed as somatic; moderate impact.
- G44V (p.Gly44Val), ExAC rs755265254, gnomAD rs755265254, CADD 26.50, PolyPhen-2 0.85
- D45Y (p.Asp45Tyr), gnomAD 12-43768244-G-T, CADD 26.60, PolyPhen-2 0.84
- D45N (p.Asp45Asn), gnomAD 12-43768244-G-A, CADD 23.30, PolyPhen-2 0.10
- D45H (p.Asp45His), gnomAD 12-43768244-G-C, CADD 25.90, PolyPhen-2 0.78
- D45D (p.Asp45Asp), gnomAD 12-43768246-T-C, CADD 8.52
- D46N (p.Asp46Asn), gnomAD 12-43768247-G-A, CADD 20.70, PolyPhen-2 0.00
- D46D (p.Asp46Asp), rs1400563632, gnomAD 12-43768249-T-C, CADD 1.70
- R47T (p.Arg47Thr), cosmic curated COSV71210
- Y48* (p.Tyr48Ter), rs2540412097, ClinGen CA2740092355, ClinVar RCV003860196, CADD 36.00, Pathogenic
- Y48X, rs779400593, []
- N49H (p.Asn49His), gnomAD 12-43768256-A-C, CADD 23.90, PolyPhen-2 0.73
- N49S (p.Asn49Ser), gnomAD 12-43768257-A-G, CADD 17.00, PolyPhen-2 0.00
- Q50* (p.Gln50Ter), TOPMed rs966984847, gnomAD rs966984847, CADD 37.00
- Q50E (p.Gln50Glu), TOPMed rs966984847, gnomAD rs966984847
- Q50L (p.Gln50Leu), rs752850989, ClinGen CA6522282, ClinVar RCV003133714, ExAC rs752850989, CADD 24.40, PolyPhen-2 0.40, Uncertain significance, Immunodeficiency 67
- Q50S (p.Gln50Ser), rs1315883092, gnomAD 12-43768257-AT-A, CADD 24.60
- Q50K (p.Gln50Lys), gnomAD 12-43768259-C-A, CADD 25.30, PolyPhen-2 0.86
- F51S (p.Phe51Ser), gnomAD 12-43768263-T-C, CADD 22.80, PolyPhen-2 0.02
- H52D (p.His52Asp), ExAC rs758634981, gnomAD rs758634981, CADD 22.20, PolyPhen-2 0.08
- H52R (p.His52Arg), Ensembl rs998929890
- H52Q (p.His52Gln), gnomAD 12-43768267-C-A, CADD 19.80, PolyPhen-2 0.63
- I53L (p.Ile53Leu), TOPMed rs1940381739
- I53V (p.Ile53Val), NCI-TCGA Cosmic COSV7121, cosmic curated COSV71210, CADD 22.10, PolyPhen-2 0.01, Variant assessed as somatic; moderate impact.
- R54K (p.Arg54Lys), rs1345805635, ClinGen CA384464787, ClinVar RCV001320858, TOPMed rs1345805635, CADD 35.00, PolyPhen-2 0.82, Uncertain significance, Immunodeficiency 67
- R54G (p.Arg54Gly), gnomAD 12-43768271-A-G, CADD 33.00, PolyPhen-2 0.94
- R54R (p.Arg54Arg), rs772625246, gnomAD 12-43771220-G-A, CADD 23.80
- R55I (p.Arg55Ile), TOPMed rs1200320958, gnomAD rs1200320958, CADD 24.50, PolyPhen-2 0.09
- R55K (p.Arg55Lys), cosmic curated COSV10471
- R55del (p.Arg55del), gnomAD 12-43771217-AAGG-, CADD 35.00
- F56Y (p.Phe56Tyr), cosmic curated COSV71210, CADD 24.10, PolyPhen-2 0.20
- F56I (p.Phe56Ile), gnomAD 12-43771224-T-A, CADD 23.10, PolyPhen-2 0.30
- F56L (p.Phe56Leu), gnomAD 12-43771224-T-C, CADD 24.50, PolyPhen-2 0.30
- E57* (p.Glu57Ter), rs1321134418, TOPMed rs1321134418, gnomAD rs1321134418, CADD 38.00, Variant assessed as somatic; high impact.
- E57K (p.Glu57Lys), rs1321134418, ClinGen CA384465894, ClinVar RCV003325264, CADD 25.80, PolyPhen-2 0.35, Uncertain significance, Immunodeficiency 67
- E57D (p.Glu57Asp), gnomAD 12-43771229-A-C, AlphaMissense 0.10, MetaLR 0.18
- A58T (p.Ala58Thr), gnomAD 12-43771230-G-A, CADD 23.20, PolyPhen-2 0.12
- L59L (p.Leu59Leu), gnomAD 12-43771233-T-C, CADD 9.70
- L59S (p.Leu59Ser), gnomAD 12-43771234-T-C, CADD 23.90, PolyPhen-2 0.05
- L59F (p.Leu59Phe), gnomAD 12-43771235-A-T, CADD 22.00, PolyPhen-2 0.01
- L60I (p.Leu60Ile), TOPMed rs1940727364
- L60F (p.Leu60Phe), gnomAD 12-43771236-C-T, CADD 18.50, PolyPhen-2 0.00
- L60H (p.Leu60His), gnomAD 12-43771237-T-A, CADD 22.90, PolyPhen-2 0.34
- Q61* (p.Gln61Ter), rs1266375962, ClinGen CA384466049, ClinVar RCV003609487, AlphaMissense 0.10, MetaLR 0.20, Pathogenic
- Q61H (p.Gln61His), ExAC rs778094168
- Q61K (p.Gln61Lys), TOPMed rs1266375962, gnomAD rs1266375962, AlphaMissense 0.10, MetaLR 0.20
- Q61Q (p.Gln61Gln), gnomAD 12-43771241-A-G, CADD 9.17
- T62A (p.Thr62Ala), rs2540425360, ClinGen CA384466107, ClinVar RCV002678233, CADD 15.20, PolyPhen-2 0.01, Uncertain significance, Inborn genetic diseases
- T62S (p.Thr62Ser), ExAC rs751881820, gnomAD rs751881820, CADD 14.40, PolyPhen-2 0.00
- G63A (p.Gly63Ala), 1000Genomes rs572719034, ExAC rs572719034, gnomAD rs572719034, CADD 24.60, PolyPhen-2 0.95
- G63E (p.Gly63Glu), cosmic curated COSV10752
- K64E (p.Lys64Glu), TOPMed rs1239693276, gnomAD rs1239693276, CADD 23.90, PolyPhen-2 0.15
- K64N (p.Lys64Asn), gnomAD rs1940729401, CADD 23.60
- K64T (p.Lys64Thr), gnomAD 12-43771249-A-C, CADD 26.10, PolyPhen-2 0.86
- S65R (p.Ser65Arg), TOPMed rs1940729721
- S65N (p.Ser65Asn), gnomAD 12-43771252-G-A, CADD 26.00, PolyPhen-2 0.90
- P66L (p.Pro66Leu), cosmic curated COSV71210
- P66P (p.Pro66Pro), rs1439926434, gnomAD 12-43771256-C-T, CADD 10.80
- T67I (p.Thr67Ile), Ensembl rs2137930820, CADD 25.30, PolyPhen-2 0.99
- S68S (p.Ser68Ser), gnomAD 12-43771262-T-G, AlphaMissense 0.19, MetaLR 0.13
- E69A (p.Glu69Ala), rs202134282, ClinGen CA6522305, ClinVar RCV001348178, ClinVar RCV004036545, CADD 24.00, PolyPhen-2 0.50, Uncertain significance, Inborn genetic diseases; Immunodeficiency 67
- L70L (p.Leu70Leu), gnomAD 12-43771266-T-C, CADD 7.93
- L71P (p.Leu71Pro), gnomAD 12-43771270-T-C, CADD 27.80, PolyPhen-2 0.99
- L71L (p.Leu71Leu), rs1940730746, gnomAD 12-43771271-G-C, AlphaMissense 0.15, MetaLR 0.23
- F72S (p.Phe72Ser), gnomAD 12-43771273-T-C, CADD 22.40, PolyPhen-2 0.01
- D73E (p.Asp73Glu), NCI-TCGA TCGA novel, ESP rs374971450, ExAC rs374971450, TOPMed rs374971450, CADD 21.80, PolyPhen-2 0.38, Likely benign
- D73H (p.Asp73His), NCI-TCGA TCGA novel, AlphaMissense 0.13, MetaLR 0.13, Variant assessed as somatic; moderate impact.
- D73D (p.Asp73Asp), rs374971450, gnomAD 12-43771277-C-T, CADD 11.20
- W74C (p.Trp74Cys), NCI-TCGA Cosmic COSV1014, cosmic curated COSV10147, Variant assessed as somatic; moderate impact.
- W74L (p.Trp74Leu), NCI-TCGA Cosmic COSV1014, cosmic curated COSV10147, Variant assessed as somatic; moderate impact.
- W74R (p.Trp74Arg), gnomAD 12-43771278-T-C, CADD 28.70, PolyPhen-2 1.00
- G75D (p.Gly75Asp), cosmic curated COSV10752
- G75S (p.Gly75Ser), ExAC rs778743146, gnomAD rs778743146, CADD 27.30, PolyPhen-2 0.96
- G75V (p.Gly75Val), gnomAD rs899354752, CADD 26.90, PolyPhen-2 1.00
- G75C (p.Gly75Cys), gnomAD 12-43771281-G-T, CADD 28.60, PolyPhen-2 0.98
- G75G (p.Gly75Gly), gnomAD 12-43771283-C-T, CADD 8.53
- T76I (p.Thr76Ile), ESP rs200175187, ExAC rs200175187, TOPMed rs200175187, gnomAD rs200175187, CADD 25.40, PolyPhen-2 0.98
- T77A (p.Thr77Ala), rs1555167569, ClinGen CA384466480, ClinVar RCV000640678, Ensembl rs1555167569, CADD 23.10, PolyPhen-2 0.11, Uncertain significance, Immunodeficiency 67
- T77K (p.Thr77Lys), ExAC rs771900851, gnomAD rs771900851, AlphaMissense 0.15, MetaLR 0.06
- T77R (p.Thr77Arg), ExAC rs771900851, gnomAD rs771900851, AlphaMissense 0.15, MetaLR 0.06
- T77del (p.Thr77del), gnomAD 12-43771282-GCAC-, CADD 19.50
- T77T (p.Thr77Thr), rs772817746, gnomAD 12-43771289-A-C, CADD 10.00
- N78D (p.Asn78Asp), rs901161233, ClinGen CA236371384, ClinVar RCV002700305, TOPMed rs901161233, CADD 22.90, PolyPhen-2 0.35, Uncertain significance, Immunodeficiency 67
- C79G (p.Cys79Gly), gnomAD 12-43771293-T-G, CADD 23.90, PolyPhen-2 0.22
- T80T (p.Thr80Thr), gnomAD 12-43771298-A-C, CADD 10.20
- V81A (p.Val81Ala), TOPMed rs997426295, CADD 27.10, PolyPhen-2 0.95
- V81F (p.Val81Phe), cosmic curated COSV71211
Public IRAK4 analysis runs
- IRAK4 analysis run — IRAK4 (816 variants) — completed 2026-08-19